Law360 (January 19, 2021, 7:22 PM EST) — Decipher Biosciences, a genomic testing company focused on prostate and bladder cancer, filed for a $100 million initial public offering Tuesday with guidance from Cooley LLP and Latham & Watkins LLP.
Companies generally use $100 million as a placeholder on their preliminary registration statements to determine related fees. Decipher Biosciences Inc. told regulators that it would use any proceeds to pay off debt and fund general corporate activity, the filing shows.
The filings with the U.S. Securities and Exchange Commission didn’t note how many shares the company was offering or what the price range would be.
Founded in 2008, San Diego,…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
